IVVD

InvivydD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.15

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.68

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.30

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-06

AI commentary

Recent coverage is mixed: clinical progress and PEMGARDA growth are supportive, while the Nasdaq deficiency is a material negative overhang. Social, options, short-interest, employee-review, and analyst-revision data are unavailable; zero values in those fields indicate missing data, not neutral evidence. This remains a cautious, event-driven monitoring setup.

RankAlpha Sentiment Codex - 2026-08-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31catalystPEMGARDA revenue and balance-sheet supportHigh impact

Q1 PEMGARDA net product revenue was $13.7 million, up 22% year over year. Q1 cash was $184.2 million, with approximately $20 million of additional gross ATM proceeds in April; major VYD2311 clinical spending was expected to end later in the summer. [#SEC-8K-2026-05-14]

2026-09-30eventDECLARATION/VYD2311 Q3 2026 topline readoutHigh impact

Invivyd says top-line data from the pivotal DECLARATION trial is anticipated in Q3 2026; the exact date is undisclosed. The readout remains highly binary. [#SEC-8K-2026-05-14]

2027-01-19eventNasdaq minimum-bid remediationHigh impact

Nasdaq notified Invivyd that its stock had closed below the $1 minimum bid requirement for 30 consecutive business days. The initial compliance deadline is January 19, 2027; failure to cure could lead to further review and possible delisting, with no assurance of compliance. [#8-K-2026-07-24]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-06 • Updated nightlySource: Internal modelMethodology